


**Patent Claims**

- 5
1. Use of selective PDE 2 inhibitors for producing pharmaceuticals for improving perception, concentration, learning and/or memory.
  2. Use according to Claim 1 for the prophylaxis and/or treatment of disorders of perception, concentration, learning and/or memory.
  3. Use according to Claim 2, where the disorder is a result of dementia.
  - 10 4. Use according to Claim 2, where the disorder is a result of stroke or craniocerebral trauma.
  5. Use according to Claim 2, where the disorder is a result of Alzheimer's disease.
  - 15 6. Use according to Claim 2, where the disorder is a result of Parkinson's disease.
  - 20 7. Use according to Claim 2, where the disorder is a result of depression.
  8. Use according to Claim 2, where the disorder is a result of dementia with frontal lobe degeneration.
  - 25 9. Use according to any of Claims 1 to 8, where the selective PDE 2 inhibitor is a compound of the general formula (I)

0911277-02201



in which

5           A=D represents N=N, N=CH or CR<sup>5</sup>=N, in which R<sup>5</sup> denotes hydrogen, methyl, ethyl or methoxy,

          R<sup>1</sup> and R<sup>2</sup> represent, together with the adjacent carbon atom, hydroxy-methylene or carbonyl, and

10          R<sup>3</sup> and R<sup>4</sup> represent independently of one another methyl, ethyl, methoxy, ethoxy or a radical of the formula SO<sub>2</sub>NR<sup>6</sup>R<sup>7</sup>,

          in which

15          R<sup>6</sup> and R<sup>7</sup> denote, independently of one another, hydrogen, C<sub>1</sub>-C<sub>6</sub>-alkyl, C<sub>3</sub>-C<sub>7</sub>-cycloalkyl, or

20          R<sup>6</sup> and R<sup>7</sup> form, together with the adjacent nitrogen atom, an azetidin-1-yl, pyrrol-1-yl, piperid-1-yl, azepin-1-yl, 4-methylpiperazin-1-yl or morpholin-1-yl radical,

or one of its salts.